CD33-Targeted Immunotherapeutics in: September 2016 R&D and Business Tracker for TCR & CAR T-Cells and NK Cells
CD33-Targeted Immunotherapeutics in:
September 2016 R&D and Business Tracker for TCR & CAR T-Cells and NK Cells
This pdf report contains information about TCR & CAR engineered T-cells and NK cells released during the month of September 2016. This issue forms part of the subscription service R&D and Business Tracker for TCR & CAR T-Cells and NK Cells
Featured presentations of September 2016 include the pipeline of CD33-targeted immunotherapeutics, the profile of US biotech Eureka Therapeutics and the profile of anti-glypican 3 CAR-T CSG-GPC3 from CARsGen Therapeutics.
The September 2016 issue of our R&D and Business Tracker service about TCR & CAR engineered T-cells and NK cells contains:
Methodology:
Information released during the previous month is retrieved from a variety of sources including corporate press releases and statements, quarterly company business reports, SEC filings, company presentations, company websites, interviews, webcasts, journal articles, scientific abstracts and reviews, relevant scientific meetings, clinical trial databases, and La Merie Publishing’s proprietary database. Relevant information is presented in textual and tabular formats with disclosure of scientific references or by a hyperlink leading to the source of information.
Customized Update Service:
The above described information service represents our standard module. At an incremental cost, the service can be exclusively widened and customized to specific client needs, e.g. preparation of a preferred presentation format, inclusion of a watch list for tracking, executive summary etc.
September 2016 R&D and Business Tracker for TCR & CAR T-Cells and NK Cells
This pdf report contains information about TCR & CAR engineered T-cells and NK cells released during the month of September 2016. This issue forms part of the subscription service R&D and Business Tracker for TCR & CAR T-Cells and NK Cells
Featured presentations of September 2016 include the pipeline of CD33-targeted immunotherapeutics, the profile of US biotech Eureka Therapeutics and the profile of anti-glypican 3 CAR-T CSG-GPC3 from CARsGen Therapeutics.
The September 2016 issue of our R&D and Business Tracker service about TCR & CAR engineered T-cells and NK cells contains:
- R&D and Technology Tracker
- Pipeline changes
- Regulatory news
- Technology validations
- Company updates
- Collaboration
- Licensing
- Merger & acquisitions
- Financing
- Scientific Publication Tracker
- Featured Cell Therapy Profile: CSG-GPC3
- Featured Company Profile: Eureka Therapuetics
- Featured Target or Technology Pipeline: CD33-Targeted Immunotherapeutics
- Antibody-Drug Conjugates
- Radio-Immunotherapeutics
- Fc-Engineered Antibodies
- T-Cell and NK Cell Redirecting Bispecific Antibodies
- CAR T-Cells
Methodology:
Information released during the previous month is retrieved from a variety of sources including corporate press releases and statements, quarterly company business reports, SEC filings, company presentations, company websites, interviews, webcasts, journal articles, scientific abstracts and reviews, relevant scientific meetings, clinical trial databases, and La Merie Publishing’s proprietary database. Relevant information is presented in textual and tabular formats with disclosure of scientific references or by a hyperlink leading to the source of information.
Customized Update Service:
The above described information service represents our standard module. At an incremental cost, the service can be exclusively widened and customized to specific client needs, e.g. preparation of a preferred presentation format, inclusion of a watch list for tracking, executive summary etc.
